CANNABINOID RESEARCH INSTITUTE

Welcome to the Brand page for “CANNABINOID RESEARCH INSTITUTE”, which is offered here for Providing online non-downloadable electronic publications in the nature of newsletters, journals, and books in the field of cannabinoid-based medicines; arranging, conducting and organisation of educational conferences, congresses, seminars and symposiums in the field of cannabinoid-based medicines; information, advisory and consultancy services in relation to all of the aforesaid services;research institute;scientific and technological services and research and design relating thereto, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services;.

Its status is currently believed to be active. Its class is unavailable. “CANNABINOID RESEARCH INSTITUTE” is believed to be currently owned by “GW Research Limited”.


Owner:
GW RESEARCH LIMITED
Owner Details
Description:
Providing online non-downloadable electronic publications in the nature of newsletters, journals, and books in the field of cannabinoid-based medicines; arranging, conducting and organisation of educational conferences, congresses, seminars and symposiums in the field of cannabinoid-based medicines; information, advisory and consultancy services in relation to all of the aforesaid services;RESEARCH INSTITUTE;Scientific and technological services and research and design relating thereto, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services;
Categories: PROVIDING ONLINE NON DOWNLOADABLE ELECTRONIC PUBLICATIONS